SI
RGNX icon

Sofinnova Investments’s Regenxbio RGNX Stock Holding History

Sofinnova Investments’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-213,959
Closed -$5.66M – 63
2022
Q3 		$5.66M Sell
213,959
-562,665
-72% -$16.7M 0.33% 43
2022
Q2 		$19.2M Buy
776,624
+162,539
+26% +$4.06M 1.6% 17
2022
Q1 		$20.4M Sell
614,085
-393,996
-39% -$10.9M 1.55% 15
2021
Q4 		$33M Buy
1,008,081
+880,488
+690% +$30M 1.93% 12
2021
Q3 		$5.35M Sell
127,593
-300,147
-70% -$10.8M 0.32% 53
2021
Q2 		$16.6M Buy
427,740
+66,005
+18% +$2.36M 0.96% 29
2021
Q1 		$12.3M Buy
361,735
+90,621
+33% +$3.86M 0.74% 30
2020
Q4 		$12.3M Buy
271,114
+211,607
+356% +$7.39M 0.73% 28
2020
Q3 		$1.64M Buy
+59,507
New +$1.94M 0.12% 64

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Sofinnova Investments's RGNX Position: Q4 2022 in Review

Sofinnova Investments sold out of Regenxbio (RGNX) in Q4 2022, closing a stake of 213,959 shares — an estimated $5.66M sold.

Sofinnova Investments first reported a position in RGNX in Q3 2020 and held it in 9 quarters. The position peaked at $33M in Q4 2021. 180 funds tracked by Wall St. Rank hold RGNX as of Q4 2022.

  • Sofinnova Investments reported no remaining Regenxbio position as of Q4 2022 after selling out during the quarter.
  • Sofinnova Investments sold 213,959 Regenxbio shares in Q4 2022, an estimated $5.66M.
  • Sofinnova Investments first reported a position in Regenxbio in Q3 2020 and held it in 9 quarters.
  • Sofinnova Investments's Regenxbio position peaked at $33M in Q4 2021.
  • 180 funds tracked by Wall St. Rank held Regenxbio as of Q4 2022.

Based on Sofinnova Investments's 13F filing for Q4 2022, filed 14 Feb 2023.